Gritstone bio Future Growth
Future criteria checks 0/6
Gritstone bio's revenue and earnings are forecast to decline at 151.3% and 2% per annum respectively while EPS is expected to grow by 13% per annum.
Key information
-2.0%
Earnings growth rate
13.0%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | -151.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation
Jun 11Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Apr 07Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -133 | N/A | N/A | 1 |
12/31/2024 | 3 | -115 | N/A | N/A | 1 |
6/30/2024 | 15 | -133 | -112 | -111 | N/A |
3/31/2024 | 16 | -145 | -118 | -115 | N/A |
12/31/2023 | 16 | -138 | -126 | -122 | N/A |
9/30/2023 | 10 | -139 | -138 | -133 | N/A |
6/30/2023 | 12 | -130 | -133 | -127 | N/A |
3/31/2023 | 15 | -125 | -128 | -123 | N/A |
12/31/2022 | 20 | -120 | -122 | -116 | N/A |
9/30/2022 | 19 | -118 | -115 | -109 | N/A |
6/30/2022 | 18 | -116 | -105 | -98 | N/A |
3/31/2022 | 16 | -112 | -101 | -95 | N/A |
12/31/2021 | 48 | -75 | -56 | -51 | N/A |
9/30/2021 | 46 | -72 | -57 | -52 | N/A |
6/30/2021 | 45 | -70 | -61 | -57 | N/A |
3/31/2021 | 42 | -71 | -58 | -55 | N/A |
12/31/2020 | 4 | -105 | -93 | -89 | N/A |
9/30/2020 | 4 | -106 | -95 | -86 | N/A |
6/30/2020 | 4 | -107 | -105 | -91 | N/A |
3/31/2020 | 4 | -103 | -104 | -89 | N/A |
12/31/2019 | 4 | -94 | -101 | -85 | N/A |
9/30/2019 | 5 | -84 | -88 | -76 | N/A |
6/30/2019 | 4 | -75 | -56 | -49 | N/A |
3/31/2019 | 3 | -69 | -49 | -42 | N/A |
12/31/2018 | 1 | -65 | -44 | -38 | N/A |
9/30/2018 | 0 | -65 | -46 | -40 | N/A |
6/30/2018 | N/A | -56 | -60 | -49 | N/A |
3/31/2018 | N/A | -47 | N/A | -44 | N/A |
12/31/2017 | N/A | -41 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRTS.Q is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GRTS.Q is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GRTS.Q is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GRTS.Q's revenue is expected to decline over the next 3 years (-151.3% per year).
High Growth Revenue: GRTS.Q's revenue is forecast to decline over the next 3 years (-151.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRTS.Q's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 12:56 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gritstone bio, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Kumar | Baird |
Corinne Johnson | Goldman Sachs |
Douglas Buchanan | JMP Securities |